A prospective study of trans-fatty acid levels in blood and risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 95-101

  Chavarro, Jorge E ^a,b   Stampfer, Meir J ^a,b   Campos, Hannia ^a   Kurth, Tobias ^a,b   Willett, Walter C ^a,b   Ma, Jing ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANS FATTY ACID;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; FAT INTAKE; FATTY ACID BLOOD LEVEL; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; LINOLEIC ACID; MALE; MIDDLE AGED; OLEIC ACID; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 38849197465     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0673     Document Type: Article

References (35)

1. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med 2006;354:1601-13.
2. Baer DJ, Judd JT, Clevidence BA, Tracy RP. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr 2004;79:969-73.
3. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 2004;79:606-12.
4. Riserus U, Basu S, Jovinge S, et al. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation 2002;106:1925-9.
5. Lefevre M, Lovejoy JC, Smith SR, et al. Comparison of the acute response to meals enriched with cis-or trans-fatty acids on glucose and lipids in overweight individuals with differing FABP2 genotypes. Metabolism 2005;54:1652-8.
6. Riserus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with metabolic syndrome. Diabetes Care 2002;25:1516-21.
7. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-81.
8. Barnard R, Aronson W, Tymchuk C, Ngo T. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002;3:303-8.
9. Brown JM, Boysen MS, Jensen SS, et al. Isomer-specific regulation of metabolism and PPARγ signaling by CLA in human preadipocytes. J Lipid Res 2003;44:1287-300.
10. Saravanan N, Haseeb A, Ehtesham NZ, Ghafoorunissa. Differential effects of dietary saturated and trans-fatty acids on expression of genes associated with insulin sensitivity in rat adipose tissue. Eur J Endocrinol 2005;153:159-65.
11. Bakker N, van't Veer P, Zock PL. Adipose fatty acids and cancers of the breast, prostate and colon: and ecological study. Int J Cancer 1997;72:587-91.
12. Schuurman AG, van den Brandt PA, Dorant E, Brants HAM, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk. Cancer 1999;86:1019-27.
13. Hodge AM, English DR, McCredie M, et al. Foods, nutrients and prostate cancer. Cancer Causes Control 2004;15:11-20.
14. King IB, Kristal AR, Schaffer S, Thornquist M, Goodman GE. Serum trans-fatty acids are associated with risk of prostate cancer in β-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2005;14:988-92.
15. Liu X, Schumacher FR, Plummer SJ, et al. Trans-fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant. Carcinogenesis 2007;28:1232-6.
16. Chavarro JE, Stampfer MJ, Li H, et al. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1364-70.
17. Baylin A, Kim MK, Donovan-Palmer A, et al. Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol 2005;162:373-81.
18. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
19. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with β carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
20. Catalona WJ, Avioli LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma [clinical conference]. Arch Intern Med 1987;147:361-3.
21. Clifton PM, Keogh JB, Noakes M. Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr 2004;134:874-9.
22. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172:S6-12.
23. Hsing AW, Gao Y-T, Chua S, Jr., Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67-71.
24. Salmeron J, Hu FB, Manson JE, et al. Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001;73:1019-26.
25. Hill EG, Johnson SB, Lawson LD, Mahfouz MM, Holman RT. Perturbation of the metabolism of essential fatty acids by dietary partially hydrogenated vegetable oil. Proc Natl Acad Sci U S A 1982;79:953-7.
26. Larque E, Garcia-Ruiz P-A, Perez-Llamas F, Zamora S, Gil A. Dietary trans fatty acids alter the compositions of microsomes and mitochondria and the activities of microsome Δ6-fatty acid desaturase and glucose-6-phosphatase in livers of pregnant rats. J Nutr 2003;133:2526-31.
27. Das UN. A defect in the activity of Δ6 and Δ5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukot Essent Fatty Acids 2005;72:343-50.
28. Lehrke M, Lazar MA. The many faces of PPAR-γ. Cell 2005;123:993-9.
29. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 2004;5:419-29.
30. Subbarayan V, Sabichi AL, Kim J, et al. Differential peroxisome proliferator-activated receptor-γ isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 2004;13:1710-6.
31. Sabichi AL, Subbarayan V, Llansa N, Lippman SM, Menter DG. Peroxisome proliferator-activated receptor-γ suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers Prev 2004;2004:1704-9.
32. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes 2003;27:S53-5.
33. Gonzalez AS, Guerrero DB, Soto MB, et al. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006;60:802-9.
34. van der Kwast TH, Ciatto S, Martikainen PM, et al. Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. Int J Cancer 2006;118:2538-42.
35. Horninger W, Reissigl A, Rogatsch H, et al. Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 2000;36:1322-35.